Literature DB >> 23623180

Analysis of genomic abnormalities in tumors: a review of available methods for Illumina two-color SNP genotyping and evaluation of performance.

Kathleen Klein Oros1, Suzanna L Arcand, Jane Bayani, Jeremy A Squire, Anne-Marie Mes-Masson, Patricia N Tonin, Celia M T Greenwood.   

Abstract

Several methods have recently been proposed for identifying copy number alterations (CNAs) in genomic DNA from tumors, using the signals arising from two-color genotyping technologies. Although copy number estimation in normal tissue has been well studied, methods developed for normal tissue tend to perform poorly when applied to tumors, due to normal cell contamination, varying levels of ploidy, and genetic heterogeneity within the tumor. Here we compare the performance of seven methods (DNA-Chip Analyzer software (dCHIP), GenoCNA software, allele-specific copy number analysis of tumors (ASCAT), OncoSNP software, genome alteration print (GAP) visualization, CNVpartition software plug-in for the Genome Studio software, and Partek Genomics Suite software) that have been established for two-color CNA analysis on the Illumina platform, using two ovarian cancer cell lines where spectral karyotyping analysis has also been performed, and two tissue samples, one from a highly malignant ovarian cancer and one from a benign ovarian tumor, all of which harbor significantly different genomic abnormalities. ASCAT shows very stable estimates of CNAs, as does OncoSNP when jointly analyzing paired normal DNA. We found the best performance, in general to be from ASCAT.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23623180     DOI: 10.1016/j.cancergen.2013.03.001

Source DB:  PubMed          Journal:  Cancer Genet


  3 in total

1.  8p deletion is strongly linked to poor prognosis in breast cancer.

Authors:  P Lebok; A Mittenzwei; M Kluth; C Özden; B Taskin; K Hussein; K Möller; A Hartmann; A Lebeau; I Witzel; S Mahner; L Wölber; F Jänicke; S Geist; P Paluchowski; C Wilke; U Heilenkötter; R Simon; G Sauter; L Terracciano; R Krech; A von der Assen; V Müller; E Burandt
Journal:  Cancer Biol Ther       Date:  2015-05-11       Impact factor: 4.742

2.  Concordance of copy number alterations using a common analytic pipeline for genome-wide analysis of Illumina and Affymetrix genotyping data: a report from the Children's Oncology Group.

Authors:  Marijana Vujkovic; Edward F Attiyeh; Rhonda E Ries; Michelle Horn; Elizabeth K Goodman; Yang Ding; Marko Kavcic; Todd A Alonzo; Robert B Gerbing; Betsy Hirsch; Susana Raimondi; Alan S Gamis; Soheil Meshinchi; Richard Aplenc
Journal:  Cancer Genet       Date:  2015-05-07

3.  Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease.

Authors:  Hubert Fleury; Laudine Communal; Euridice Carmona; Lise Portelance; Suzanna L Arcand; Kurosh Rahimi; Patricia N Tonin; Diane Provencher; Anne-Marie Mes-Masson
Journal:  Genes Cancer       Date:  2015-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.